Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Significant Increase in Short Interest

Avenue Therapeutics, Inc. (NASDAQ:ATXIGet Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 80,600 shares, an increase of 258.2% from the December 31st total of 22,500 shares. Currently, 4.6% of the shares of the stock are sold short. Based on an average daily volume of 358,600 shares, the days-to-cover ratio is presently 0.2 days.

Avenue Therapeutics Stock Performance

ATXI stock traded up $0.04 during mid-day trading on Friday, reaching $1.36. 101,545 shares of the stock traded hands, compared to its average volume of 1,105,412. The business has a 50-day moving average price of $1.84 and a two-hundred day moving average price of $2.28. The stock has a market capitalization of $2.79 million, a PE ratio of 0.07 and a beta of -0.27. Avenue Therapeutics has a one year low of $1.26 and a one year high of $15.00.

Institutional Investors Weigh In On Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC bought a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXIFree Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned about 1.17% of Avenue Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 17.34% of the company’s stock.

Avenue Therapeutics Company Profile

(Get Free Report)

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.

Featured Stories

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.